Company Overview

黄石世星药业有限责任公司

HUANGSHI SHI XING PHARMACEUTICAL CO., LTD

黄石世星药业有限责任公司

HUANGSHI SHI XING PHARMACEUTICAL CO., LTD

黄石世星药业有限责任公司

HUANGSHI SHI XING PHARMACEUTICAL CO., LTD

黄石世星药业有限责任公司

HUANGSHI SHI XING PHARMACEUTICAL CO., LTD

Company Overview

Company Introduction

       The company, formerly known as Huangshi No. 4 Pharmaceutical Factory, was established in 1992. Located at No. 73, East Jinshan Avenue, Jinshan Development Zone, Huangshi City, Hubei Province, it covers an area of 200 mu and employs over 450 people. The company is a national-level "high-tech enterprise," "AAA-level credit enterprise," national green factory, Hubei Province's pillar industry sub-sector "small giant enterprise in science and technology," and Hubei Province's specialized, refined, and new "small giant" enterprise. It has passed ISO9001 quality, ISO14001 environmental, ISO45001 occupational health and safety, and ISO50001 energy management system certifications. It has also won the Hubei Provincial Center Enterprise Innovation Award and three Hubei Provincial Science and Technology Progress Awards. 
      The company's main business is the production, sales, and technical services of pharmaceutical raw materials and intermediates, belonging to the field of biological and new pharmaceutical national basic drug raw materials and important intermediate technologies. 
      The company's main products include more than ten raw materials for macrolide antibiotics, antipyretics and analgesics, non-steroidal anti-inflammatory drugs, brain metabolism improvers, cardiotonic drugs, proton pump inhibitors, and antiviral ophthalmic drugs, with 70% of its products exported. It has the most complete range of macrolide antibiotics domestically and internationally, including azithromycin, clarithromycin, roxithromycin, erythromycin ethylsuccinate, and erythromycin estolate (5 varieties). Its production capacity and market share rank among the top domestically and internationally. It is the sole domestic producer of ketoprofen tromethamine, an antipyretic and analgesic, non-steroidal anti-inflammatory drug, accounting for 80% of the international market share. The company's azithromycin has passed the EU CEP certification, and roxithromycin has passed the Japanese MF certification. 
      The company adheres to the philosophy of "people-oriented, focusing on health, striving for excellence, and green development." It is committed to the development of pharmaceutical raw material industries and human health, striving to become a world-class pharmaceutical company.